Vimarsana
Biggest News Aggregation in the World

Page 16 - Kronos Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kronos Bio Today - Breaking & Trending Today

Marianne De Backer, MSc, PhD, MBA - BIO International Convention - Vimarsana News

Marianne De Backer, MSc, PhD, MBA - BIO International Convention

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.

Source: bio.org
Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress - Vimarsana News

Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia Additional presentations... | May 12, 2022

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development - Vimarsana News

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute...

Reviewing Clovis Oncology (NASDAQ:CLVS) and Kronos Bio (NASDAQ:KRON) - Vimarsana News

Reviewing Clovis Oncology (NASDAQ:CLVS) and Kronos Bio (NASDAQ:KRON)

Clovis Oncology (NASDAQ:CLVS – Get Rating) and Kronos Bio (NASDAQ:KRON – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk. Earnings & Valuation This table compares Clovis Oncology and […]

Leen Kawas Business Partner Stirs Up More Drama at Athira - Vimarsana News

Leen Kawas Business Partner Stirs Up More Drama at Athira

Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne's calls for a management change.